Related Experiment Video
Updated: May 7, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Potential synergy between tau aggregation inhibitors and tau chaperone modulators
Laura J Blair1, Bo Zhang1, Chad A Dickey1
1Department of Molecular Medicine, University of South Florida, 4001 E. Fletcher Avenue, MDC 36,, Tampa, FL 33613, USA.
Alzheimer'S Research & Therapy
|September 18, 2013
Summary
Developing therapeutics for tauopathies, like Alzheimer's disease, is crucial. This review focuses on drugs that inhibit tau aggregation and enhance its clearance, exploring combination strategies despite challenges.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Tau protein aggregates are hallmarks of neurodegenerative tauopathies, including Alzheimer's disease.
- Current therapeutic options for tauopathies are limited, with only one drug in Phase III trials.
- Aberrant tau aggregation leads to neuronal dysfunction and death.
Purpose of the Study:
- To review existing and emerging therapeutics targeting tau pathology.
- To explore strategies for inhibiting tau aggregation and promoting its clearance.
- To discuss the potential of combination therapies for tauopathies.
Main Methods:
- Literature review of drugs affecting tau biology.
- Analysis of aggregation inhibitors and chaperone modulators.
- Evaluation of therapeutic approaches for tauopathies.
Main Results:
- Various drug classes, including kinase inhibitors and chaperone modulators, can alter tau aggregation and levels.
- Heat shock protein modulators show promise in preclinical tau models.
- Combining different therapeutic strategies may offer optimal outcomes.
Conclusions:
- Targeting tau aggregation and clearance presents a promising therapeutic avenue for tauopathies.
- Challenges include off-target effects and blood-brain barrier penetration of drug candidates.
- Further research into synergistic therapeutic combinations is warranted.
Related Concept Videos
03:00Molecular Chaperones and Protein Folding
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
03:00Molecular Chaperones and Protein Folding
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:42Microtubule Associated Proteins (MAPs)
Microtubule function and architecture are regulated by an array of specialized proteins called microtubule-associated proteins or MAPs. These proteins are widespread across different organisms and have conserved protein motifs, like the multi-TOG domain for tubulin binding found in the CLASP family of MAPs. Some MAPs are lineage-specific based on their conserved domains. Their functions depend upon the cytoskeletal architecture and cell type they are located within. In-plant cells, a specific...